Nov.10 -- Eli Lilly & Co. Chairman and Chjef Executive Officer David Ricks discusses the drugmaker's Covid-19 antibody therapy bamlanivimab, which was recently granted an emergency-use authorization by the U.S. Food and Drug Administration. He speaks on "Bloomberg Surveillance."